Literature DB >> 21204227

Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations.

Sarah M Nielsen1, Wendy S Rubinstein, Darcy L Thull, Michaele J Armstrong, Eleanor Feingold, Michael T Stang, James R Gnarra, Sally E Carty.   

Abstract

Von Hippel-Lindau (VHL) disease type 2A is an inherited tumor syndrome characterized by predisposition to pheochromocytoma (pheo), retinal hemangioma (RA), and central nervous system hemangioblastoma (HB). Specific VHL subtypes display genotype-phenotype correlations but, unlike other familial syndromes such as MEN-2, the phenotype in VHL has not yet been stratified at the codon level. Over decades, we have managed two very large VHL type 2A regional kindreds with nearly adjacent but distinct VHL missense mutations. We determined the phenotype of Family 2 and compared the clinical and pathologic parameters of pheo between 30 members of Family 1 (Y112H mutation) and 33 members of Family 2 (Y98H mutation) with mean follow-up of 15.5 and 12.1 years, respectively (P = 0.24). In Family 2, pheo was the most frequent VHL manifestation (79%) and all pheo diagnoses occurred by age 50. Age at first diagnosis was younger in Family 2 than in Family 1 (mean 19.7 vs. 28.8 years; P = 0.02). Pheo expressivity differed by genotype: Family 1 pheo was more likely to be multifocal (P = 0.04), as well as malignant (P < 0.01) and lethal (P = 0.02). Family 1 pheo was also more likely to secrete vanillylmandelic acid (VMA) alone (P = 0.05). This analysis of 130 pheochromocytomas in 63 VHL type 2A patients demonstrates that mutation-specific malignancy and expression patterns exist within the VHL type 2A subtype, and provides information that may help tailor the screening and management algorithms of affected members and those at risk.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204227      PMCID: PMC3085839          DOI: 10.1002/ajmg.a.33760

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  24 in total

1.  Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene.

Authors:  J F Bradley; D L Collins; R N Schimke; H N Parrott; P G Rothberg
Journal:  Am J Med Genet       Date:  1999-11-19

Review 2.  Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus.

Authors:  H P Neumann; O D Wiestler
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

3.  Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus.

Authors:  G M Glenn; L N Daniel; P Choyke; W M Linehan; E Oldfield; M B Gorin; S Hosoe; F Latif; G Weiss; M Walther
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

4.  Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery.

Authors:  Mercedeh Baghai; Geoffrey B Thompson; William F Young; Clive S Grant; Virginia V Michels; Jon A van Heerden
Journal:  Arch Surg       Date:  2002-06

5.  Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3.

Authors:  S Hosoe; H Brauch; F Latif; G Glenn; L Daniel; S Bale; P Choyke; M Gorin; E Oldfield; A Berman
Journal:  Genomics       Date:  1990-12       Impact factor: 5.736

6.  Vascular and metabolic effects of circulating epinephrine and norepinephrine. Concentration-effect study in dogs.

Authors:  P Hjemdahl; E Belfrage; M Daleskog
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

7.  Molecular characterization and ophthalmic investigation of a large family with type 2A Von Hippel-Lindau Disease.

Authors:  R C Allen; A R Webster; R Sui; J Brown; C M Taylor; E M Stone
Journal:  Arch Ophthalmol       Date:  2001-11

8.  Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.

Authors:  Zoran Erlic; Lisa Rybicki; Mariola Peczkowska; Henriette Golcher; Peter H Kann; Michael Brauckhoff; Karsten Müssig; Michaela Muresan; Andreas Schäffler; Nicole Reisch; Matthias Schott; Martin Fassnacht; Giuseppe Opocher; Silke Klose; Christian Fottner; Flavio Forrer; Ursula Plöckinger; Stephan Petersenn; Dimitry Zabolotny; Oleg Kollukch; Svetlana Yaremchuk; Andrzej Januszewicz; Martin K Walz; Charis Eng; Hartmut P H Neumann
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

Review 9.  Pheochromocytoma: the expanding genetic differential diagnosis.

Authors:  Jennifer Bryant; Jennifer Farmer; Lisa J Kessler; Raymond R Townsend; Katherine L Nathanson
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

10.  Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series.

Authors:  M G Sutton; S G Sheps; J T Lie
Journal:  Mayo Clin Proc       Date:  1981-06       Impact factor: 7.616

View more
  6 in total

1.  Long-term outcomes, branch-specific expressivity, and disease-related mortality in von Hippel-Lindau type 2A.

Authors:  Sarah M Nielsen; Wendy S Rubinstein; Darcy L Thull; Michaele J Armstrong; Eleanor Feingold; Linwah Yip; Samuel A Tisherman; Sally E Carty
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

2.  Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family.

Authors:  T Mete; D Berker; E Yilmaz; G Ozgen; Y Yalcin; M Tuna; D Ciliz; M Onen; Y Aydin; S Guler
Journal:  Endocrine       Date:  2013-05-15       Impact factor: 3.633

3.  Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Authors:  Sena Hwang; Cheol Ryong Ku; Ji In Lee; Kyu Yeon Hur; Myung-Shik Lee; Chul-Ho Lee; Kyo Yeon Koo; Jin-Sung Lee; Yumie Rhee
Journal:  J Hum Genet       Date:  2014-07-31       Impact factor: 3.172

Review 4.  Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack.

Authors:  João Castro-Teles; Bernardo Sousa-Pinto; Sandra Rebelo; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2021-10-27       Impact factor: 3.335

5.  Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata.

Authors:  Michael Ohh; Cassandra C Taber; Fraser G Ferens; Daniel Tarade
Journal:  Elife       Date:  2022-08-30       Impact factor: 8.713

6.  Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel-Lindau Disease.

Authors:  Baoan Hong; Kaifang Ma; Jingcheng Zhou; Jiufeng Zhang; Jiangyi Wang; Shengjie Liu; Zhongyuan Zhang; Lin Cai; Ning Zhang; Kan Gong
Journal:  Front Genet       Date:  2019-09-18       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.